DNA Methylation Detection Kit for Human PAX1, SOX1 and HAS1 Gene

PCR-based fluorescence detection kit for identifying multi-gene methylation patterns in colorectal cancer screening and diagnosis. Enables risk stratification, early detection, treatment guidance, and post-operative monitoring through molecular analysis of epigenetic biomarkers.

Gene methylation-based diagnostic test for early detection of hepatocellular carcinoma with industry-leading performance metrics. This blood-based test enables non-invasive screening for liver cancer risk stratification. The product is approved by NMPA and integrated into multiple hospital and insurance systems.

The world's first approved gene methylation early detection product for esophageal cancer, representing a breakthrough in early cancer diagnosis. This product has received NMPA certification and is part of BioChain's comprehensive digestive system cancer screening portfolio.

A diagnostic test kit for the combined detection of multiple gene methylation markers in blood samples for colorectal cancer screening and detection using methylation analysis technology.

A blood-based gene methylation early detection product for colorectal cancer that was the first in China to receive NMPA approval and is marketed under the brand name Siboding®. The product has received authorizations from the FDA, NMPA, and EU CE, representing the world's earliest simultaneous approval from all three major regulatory bodies.

A diagnostic test series analyzing 136 genes for cancer-specific detection and classification. This panel supports tumor profiling and prognostic assessment across multiple cancer types.

Multi-gene methylation detection test for colorectal cancer screening and risk assessment. Uses advanced liquid biopsy technology to identify epigenetic biomarkers associated with colorectal malignancy. Enables non-invasive early detection and personalized patient stratification for clinical decision-making.

A blood-based gene methylation detection kit for hepatocellular carcinoma with industry-leading performance metrics. This approved product is part of BioChain's comprehensive coverage of major digestive system cancers.

The world's first approved gene methylation early detection product for gastric cancer, filling a gap in both domestic and international markets and marketed as Sibowei®. This innovative Class III medical device has received NMPA approval and addresses the early diagnosis needs for gastric cancer patients.

A diagnostic test kit for the detection of mutations in the human POLE gene. This product is used for in vitro detection of POLE gene mutations in clinical samples.

In vitro qualitative detection kit for 15 high-risk HPV E6/E7 mRNA subtypes in cervical exfoliated cell samples. Detects HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68 for cervical cancer and precancerous lesion risk assessment. NMPA Class III medical device registered.

A diagnostic test kit for detecting multiple gene methylation markers in blood samples for intestinal cancer screening and diagnosis. The product is marketed under the brand name Chang Ai Ke® and represents an in vitro diagnostic solution for cancer detection.